PTC Therapeutics (PTCT) Misses Q4 EPS by 14c, Revenues Beat

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($1.08), $0.14 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $118.86 million versus the consensus estimate of $111.36 million.

"Despite the challenges of the pandemic, PTC has been able to make significant progress in moving our pipeline forward and has been able to continue to bring therapies to our patients throughout 2020," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "I am very proud of our team and their abilities to execute on our 2020 goals even in such turbulent times. I am confident that we will continue to progress on our 2021 goals that will create value for all of our stakeholders."

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Beneficient CEO confirmed, former chief convicted in fiscal 2026 update
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Contango settles $18.75M Lucky Shot obligations for $6.57M